Fontenay le Fleury, France

Jean-Marie Bernard


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 1990

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Jean-Marie Bernard

Introduction

Jean-Marie Bernard is a notable inventor based in Fontenay le Fleury, France. He has made significant contributions to the field of biochemistry, particularly through his innovative work on muramylpeptide derivatives. His research focuses on enhancing the properties of these compounds to activate macrophages, which play a crucial role in the immune response.

Latest Patents

Jean-Marie Bernard holds a patent for "Lipophile derivatives of muramylpeptides having properties of activating." This invention relates to muramylpeptide derivatives that result from the conjugation or coupling of a muramylpeptide with a group containing two atoms, each attached to a lipophile chain comprising between 8 to 100 carbon atoms. The derivatives exhibit remarkable stimulating properties that amplify the tumoricidal capabilities of macrophages.

Career Highlights

Throughout his career, Jean-Marie Bernard has been associated with the Agence Nationale De Valorisation De La Recherche (ANVAR), where he has contributed to various research initiatives. His work has been instrumental in advancing the understanding of immune system activation and its potential applications in medical therapies.

Collaborations

Jean-Marie Bernard has collaborated with esteemed colleagues, including Nigel Phillips and Francoise Marguerite Audibert. These partnerships have fostered a collaborative environment that enhances the research and development of innovative solutions in the field.

Conclusion

Jean-Marie Bernard's contributions to the field of biochemistry through his innovative patents and collaborations highlight his commitment to advancing medical science. His work on muramylpeptide derivatives showcases the potential for significant advancements in immune response therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…